Roche Acquires Ignyta for $1.7B

The Swiss company plans to buy the US cancer drugmaker in order to increase the range of its global oncology portfolio
Dec. 26, 2017

Roche has announced plans to buy U.S. cancer drugmaker Ignyta Inc for $1.7 billion. The move is meant to increase the company's global oncology portfolio.

Ignyta's operations will continue in San Diego alongside its study of entrectinib, the company's most advanced drug.

The deal is expected to close in the first half of 2018.

Read the CNBC report

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates

Related

Eli Lilly’s new Concord, North Carolina site was built with NASCAR-like speed
Celltrion to buy US biologics manufacturing plant as part of tariff response strategy
OnTrak Wireless: Total Bearing Health Solution
Sponsored
OnTrak Wireless & UltraTrak Vario Lubricators: Bearing Health Unified
Sponsored